Sanyou Biopharmaceuticals Announces Line of Monkeypox Treatments
The product line includes vaccines, monoclonal antibodies, and antigens.
Stock.adobe.com
In response to continued spread of monkeypox, Sanyou Biopharmaceuticals announced that it is launching a comprehensive line of monkeypox-targeting products.1 This includes vaccines, treatments, and antigens.
According to a press release, Sanyou is producing 65 items as part of this line. This includes 26 different antigens, 28 monoclonal antibody treatments, and 11 overexpression cell lines. These treatments should be effective against a variety of monkeypox strains.
Some of these treatments were developed using Sanyou’s antibody discovery platform. Earlier this month, Sanyou announced that it had officially launched its Innovative Intelligent Antibody Design oneClick+ Platform.2 The platform allows users to create antibody sequences, which then generates antibody reports.
In a press release issued at the time, Sanyou Bio’s CEO Dr. Guojun Lang said, “With the rapid development of intelligent technology, the intelligent construction of biologic drugs has become an inevitable path for industry development. It has also become a powerful engine for improving customer experience, simplifying business processes, and optimizing operational efficiency. The launch of the 'oneClick+' platform marks a significant step forward for Sanyou Bio in the field of intelligent antibody design. The convenience it offers will completely revolutionize the way users approach antibody design. We believe that the launch of the 'oneClick+' platform will provide our customers with an unprecedented experience and contribute to the intelligent development of the biopharmaceutical industry. Let us look forward to a brighter and better future for biologic drugs with the support of intelligent technology!"
Sanyou also announced this month that it had partnered with JiAnTeBo Biotechnology to jointly develop new agonist antibody drugs.3
In a press release issued at the time, JiAnTeBo founder professor Yin Zhinan said, “We will always be committed to finding innovative therapies in the field of metabolic diseases such as obesity, diabetes, fatty liver, and Alzheimer's disease. By partnering with Sanyou Bio, we will leverage their expertise technology and innovation capabilities in the field of antibodies and based on our existing protein pipeline and mRNA new drug pipeline, to accelerate the layout of our original research pipeline and promote the development of agonist antibody drugs, thus bringing more effective treatment options to patients suffering major diseases around the world."
In the same press release, Goujun added, “We are thrilled to partner on R&D with JiAnTeBo, an excellent team dedicated to pioneering innovative therapies. With Sanyou Bio's three major innovative drug R&D technology platforms: 'Super-Trillion, Integration, Intelligence,' we are confident in our ability to better assist JiAnTeBo in completing the strategic layout of innovative biological drugs. The strong alliance of the two parties will definitely bring new hope to more tumor and metabolic patients."
Sources
- Sanyou Bio Launches Comprehensive Monkeypox Product Line. Sanyou Bio. August 30, 2024. https://www.prnewswire.com/news-releases/breaking-news--sanyou-bio-launches-comprehensive-monkeypox-product-line-302234806.html
- Sanyou Bio's Innovative Intelligent Antibody Design oneClick+ Platform is Officially Launched. Sanyou Bio. August 15, 2024. Accessed August 30, 2024. https://www.prnewswire.com/news-releases/sanyou-bios-innovative-intelligent-antibody-design-oneclick-platform-is-officially-launched-302223431.html
- Sanyou Pharmaceuticals and JiAnTeBo Biotechnology Forge Strategic Partnership to Jointly Develop New Agonist Antibody Drugs. Sanyou Bio. August 7, 2024. Accessed August 30, 2024. https://www.prnewswire.com/news-releases/sanyou-pharmaceuticals-and-jiantebo-biotechnology-forge-strategic-partnership-to-jointly-develop-new-agonist-antibody-drugs-302216465.html
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
